Company: CERO
Filing Date: 2025-11-19
Form Type: 10-Q
Source: 0001213900-25-112619
Chunk: 99

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-11-19
Form: 10-Q
Item: Item 1
Chunk 99
---
 the Nine Months Ended September 30,  

    2024  

    2025 (Successor)  
    (Pro forma, Predecessor and Successor)  
    Difference 

    Net cash used in operating activities 
    $(12,273,817) 
    $(11,375,873) 
    $(897,944)
  
    Net cash provided by investing activities 
     500,000  
     -  
     500,000 
  
    Net cash provided by financing activities: 
     10,468,829  
     12,240,682  
     (1,771,853)
  
    Net (decrease) increase in cash, restricted cash and cash equivalents 
    $(1,304,988) 
    $864,809  
    $(2,169,797)

Net cash used in operating activities

Net cash used in operating activities for the nine months ended September
30, 2025 primarily reflected a net loss of $15,380,000, adjusted for the reconciliation of non-cash items such as depreciation expense
of $215,000, stock-based compensation of $836,000, stock-based inducement expense of $864,000, write off of deferred offering costs of
$500,000, and amortization of right-of-use asset of $595,000, and changes in operating asset and liabilities primarily consisting of an
increase in prepaid expenses and other current assets of $257,000, an increase in accounts payable of $1,426,000, a decrease in accrued
liabilities of $429,000, and a decrease in operating lease liabilities of $644,000.

Net cash used in operating
activities for the nine months ended September 30, 2024 primarily reflected a net loss of $8,976,000, adjusted for the reconciliation
of non-cash items such as a gain of settlement of liabilities with vendors of $589,000, depreciation expense of $342,000, stock-based
compensation of $1,904,000, amortization of right-of-use asset of $537,000 and a gain on revaluation of earnout liability and the preferred
stock warrant liability of $5,190,000, and changes in operating asset and liabilities primarily consisting of a decrease in accounts
payable of $232,000, an increase in accrued liabilities of $1,476,000, and a decrease in operating lease liabilities of